Boston, US-based PureTech Health has appointed Dr Atul Pande as its new chief medical officer, responsible for the firm's pipeline in immune, nervous and gastro-intestinal systems.
Dr Pande was formerly senior vice president and head of neuroscience at GlaxoSmithKline, where he also served as a senior advisor in its R&D division.
Prior to this, he was chief medical officer at Cenerx Biopharma and brings further R&D leadership experience from Pfizer, where he served as vice president for neurosciences.
Dr Pande currently serves on the board of directors for Karuna Pharmaceuticals - part of PureTech Health - as well as Axovant Sciences, Autifony Therapeutics, and Cennerv Pharma's scientific advisory board.
Daphne Zohar, chief executive officer of PureTech Health, said: “We are excited to work more closely with Atul and to have access to his drug development expertise across PureTech Health's pipeline.
“Atul is a seasoned drug development veteran who will help to shepherd our advancing pipeline through mid- and late-stage clinical trials while ensuring that synergies are leveraged across our platforms.”
No results were found
We know what it takes to create brands, to start new conversations, to simply communicate complex science, to change lives…...